Elektrofi, a startup that helps drugmakers formulate biologics for easier delivery, is raising a $112M Series C

Bi­o­log­ics start­up Elek­trofi is rais­ing an ap­prox­i­mate­ly $112 mil­lion Se­ries C, CEO and co-founder Chase Coff­man con­firmed to End­points News.

The Boston-based start­up works with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Actemra Biosimilar Approved

The FDA has approved the first biosimilar version of the interleukin-6 (IL-6) blocker tocilizumab, to be marketed as Tofidence and with indications for rheumatoid arthritis

Read More »